News | April 21, 2023
SÜDPACK’s PharmaGuard blister concept to add to sustainability
SÜDPACK is setting standards in terms of both performance and sustainability
SÜDPACK is setting standards in terms of both performance and sustainability
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
